CA2208233A1 - Utilisation de molecules se fixant a cnh-ii et/ou simulant cnh-ii dans la prevention et/ou le traitement des etats inflammatoires - Google Patents

Utilisation de molecules se fixant a cnh-ii et/ou simulant cnh-ii dans la prevention et/ou le traitement des etats inflammatoires

Info

Publication number
CA2208233A1
CA2208233A1 CA002208233A CA2208233A CA2208233A1 CA 2208233 A1 CA2208233 A1 CA 2208233A1 CA 002208233 A CA002208233 A CA 002208233A CA 2208233 A CA2208233 A CA 2208233A CA 2208233 A1 CA2208233 A1 CA 2208233A1
Authority
CA
Canada
Prior art keywords
mhc
molecules
lps
cell
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002208233A
Other languages
English (en)
Inventor
Roger Pascal Lauener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires OM SA
DEUTSCHE OM ARZNEIMITTEL GmbH
Original Assignee
Laboratories Om SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratories Om SA filed Critical Laboratories Om SA
Publication of CA2208233A1 publication Critical patent/CA2208233A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La présente invention se rapporte à des molécules se fixant à CMH-II (complexe majeur d'histocompatibilité) et/ou simulant CMH-II, ces molécules servant à intervenir dans l'interaction entre un stimulus d'activation des cellules porteuses de CMH-II telles que les phagocytes et des molécules de CMH-II liées aux cellules. Ces molécules interviennent également dans l'interaction entre un lipopolysaccharide ou LPS dans un complexe avec d'autres molécules, telles que CD14 et LBP (protéines de liaisons de LPS), et des molécules CMH-II liées aux cellules, ou dans l'interaction entre des produits provenant de bactéries Gram positif ou des complexes de produits provenant de bactéries Gram positif avec des molécules telles que CD14, et des molécules de CMH-II liées aux cellules. La molécule de fixation de CMH-II peut être n'importe quel anticorps ou fragment d'anticorps anti-CMH-II, ou n'importe quelle molécule dérivée de cet anticorps tel que des molécules humanisées, plus spécifiques ou autres molécules mises au point. La molécule de fixation de CMH-II peut être sélectionnée dans le groupe constitué par CD14, des fragments de celui-ci, des versions modifiées de celui-ci ou des peptides possédant des propriétés de fixation à CMH-II.
CA002208233A 1994-12-23 1995-12-27 Utilisation de molecules se fixant a cnh-ii et/ou simulant cnh-ii dans la prevention et/ou le traitement des etats inflammatoires Abandoned CA2208233A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
EP94203755.7 1994-12-23

Publications (1)

Publication Number Publication Date
CA2208233A1 true CA2208233A1 (fr) 1996-07-04

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208233A Abandoned CA2208233A1 (fr) 1994-12-23 1995-12-27 Utilisation de molecules se fixant a cnh-ii et/ou simulant cnh-ii dans la prevention et/ou le traitement des etats inflammatoires

Country Status (11)

Country Link
EP (1) EP0800534A2 (fr)
JP (1) JPH10511652A (fr)
CN (1) CN1171117A (fr)
AU (1) AU4347696A (fr)
BR (1) BR9510554A (fr)
CA (1) CA2208233A1 (fr)
CZ (1) CZ186897A3 (fr)
HU (1) HUT77468A (fr)
PL (1) PL320922A1 (fr)
SK (1) SK80697A3 (fr)
WO (1) WO1996020215A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
AU729406B2 (en) 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (fr) * 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
HU228957B1 (en) * 2001-07-02 2013-07-29 Aimsco Ltd Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
MXPA04007311A (es) * 2002-01-28 2005-05-16 Aimsco Ltd Tratamiento de ms con suero de cabra.
ES2232273B1 (es) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos Nuevas aplicaciones terapeuticas de la glucoproteina cd14s.
AU2004241069B2 (en) * 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (fr) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Méthode immunothérapeutique allèle spécifique et forme de dosage
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
JPS6225994A (ja) * 1985-05-30 1987-02-03 ジエネテイツク　システムズ　コ−ポレイシヨン Ｈｌａタイプ分け用モノクロ−ナル抗体
JPS63275526A (ja) * 1987-05-03 1988-11-14 Hiroshi Okajima Ｈｉｖウイルス中和抗体
FR2658197B1 (fr) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993010220A1 (fr) * 1991-11-19 1993-05-27 Anergen, Inc. Molecules solubles du complexe majeur d'histocompatibilite et leurs utilisations
CA2133758A1 (fr) * 1992-04-06 1993-10-14 Sanna M. Goyert Nouveau mode de traitement de la septicemie utilisant une forme soluble d'antigene myelomonocytaire cd14 recombinant
KR0169751B1 (ko) * 1992-10-15 1999-01-15 마에다 카쭈노수케 주요 조직 적합성 항원 클라스ii 단백질의 제조방법 및 그것을 고정화한 재료
AU695124B2 (en) * 1993-05-28 1998-08-06 Scripps Research Institute, The Methods and compositions for inhibiting CD14 mediated cell activation
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
SK80697A3 (en) 1997-12-10
CN1171117A (zh) 1998-01-21
JPH10511652A (ja) 1998-11-10
WO1996020215A3 (fr) 1996-10-10
HUT77468A (hu) 1998-05-28
WO1996020215A2 (fr) 1996-07-04
AU4347696A (en) 1996-07-19
BR9510554A (pt) 1999-06-29
CZ186897A3 (cs) 1998-03-18
EP0800534A2 (fr) 1997-10-15
PL320922A1 (en) 1997-11-10

Similar Documents

Publication Publication Date Title
CN109311991B (zh) Baff-r靶向嵌合抗原受体修饰的t细胞及其用途
Rivoltini et al. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing
CA2689242C (fr) Agent et procede pour le traitement du cancer
US7390490B1 (en) Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
EP3469362A1 (fr) Récepteurs de lymphocytes t gamma delta restreints à l'antigène leucocytaire humain et leurs méthodes d'utilisation
US8455444B2 (en) CDH3 peptide and medicinal agent comprising the same
US20070212370A1 (en) Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
TW201041593A (en) Cancer antigen helper peptide
JPS6362519B2 (fr)
LT4225B (en) Immuno-stimulatory monoclonal antibodies
CA2208233A1 (fr) Utilisation de molecules se fixant a cnh-ii et/ou simulant cnh-ii dans la prevention et/ou le traitement des etats inflammatoires
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
KR100850731B1 (ko) Ｐ-셀렉틴 당단백질 리간드 1의 조절자
JPH09509646A (ja) 多発性硬化症を治療する方法
CN114401991A (zh) 用于调节髓系细胞炎性表型的抗siglec-9组合物和方法及其用途
US9102726B2 (en) Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
EP1367393A1 (fr) Procédé d'utilisation de la voie CD 163 pour la modulation d'une réponse Immunitaire
AU6316799A (en) Use of MCH-II binding and/or MHC-II mimicking molecules for the prevention and/or treatment of inflammatory diseases
JP2016069314A (ja) 免疫抑制剤
WO2023216440A1 (fr) Tcr reconnaissant de manière spécifique un peptide d'antigène prame et son utilisation
Erbe Functional studies of human IgG Fc receptors

Legal Events

Date Code Title Description
FZDE Discontinued